TRICALS response to the approved RELYVRIO Drug in America  - IMNDA

TRICALS response to the approved RELYVRIO Drug in America 

October 6th, 2022

TRICALS response to the approved RELYVRIO Drug for American Market. TRICALS 300x118

Food and Drug Administration (FDA) approves AMX0035 (Amylyx) for the American market.

During a meeting of the FDA’S Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) on Thursday September 29 2022, the Amylyx drug AMX0035 received conditional approval under the name RELYVRIO. This means that Relyvrio is available for American citizens. What does this approval mean and how does this affect patients in Europe?  



Relyvrio is still being investigated in Europe in a phase 3 trial called Phoenix. This trial is necessary because the existing trial results for Relyvrio do not provide the level of evidence required by the European regulatory authorities that Relyvrio is an effective treatment for MND. The FDA agree with this assessment of the evidence and have made the final approval of Relyvrio dependent on successful completion of the current Phoenix trial in Europe.


Difference between a phase 2 and phase 3 study

A phase 2 and a phase 3 study differ from each other in the number of participants and the duration of treatment. The more participants and the longer the treatment, the better the evidence about the effect and safety of the drug. In the past many phase 2 studies have suggested a benefit but when the larger phase 3 study has been done the benefit seemed to disappear. The results from the phase 2 study therefore turned out to be ‘false positive’. Normally, the FDA and EMA make decisions based on the results of a phase 3 study. Amylyx submitted a request to the FDA and EMA to make a decision on early admission to the US market based on the results from the completed phase 2 study. This decision was postponed by the FDA earlier this year but has now been approved at its September meeting. The same request for early admission to the European market is currently under consideration by the EMA. AMX0035 can only be admitted to the European market if the EMA gives a positive assessment.


What does this mean for people living with ALS/MND in Europe?

People living with ALS will wonder whether they can also gain access to the drug through the US market. Relyvrio can only be prescribed through an attending physician in America. We do not know yet whether the American insurance companies will pay for this drug. In countries where Relyvrio is not approved currently, doctors cannot prescribe the drug. In most countries, the costs of treatment with Relyvrio will not be met by the government or insurance companies.


The Phoenix trial in Europe

The results from the current phase 3 study are needed to ensure that the drug Relyvrio has a definite positive effect on those living with ALS/MND. If the EMA surprised the community and did not wait for the Phoenix results but instead approved Relyvrio on the phase 2 data from Centaur, this would not mean Relyvrio would be automatically available in Europe.  To be available health systems and insurers must review the trial data and decide whether they will pay for Relyvrio for their population of patients. Without the high quality phase 3 data being collected in Phoenix it is likely that many will not agree to pay for Relyvrio.


More information about the Phoenix study and the contact details of participating TRICALS centers, can be found on our website.


How does AMX0035 work?

AMX0035 is a combination of two agents: sodium phenylbutyrate and tauursodiol (TUDCA) and is administered orally by dissolving the agent in a glass of water. The active substances in AMX0035 enhance each other’s influence on the energy factories of the body, the mitochondria, and reduce oxygen damage in cells. These are important clues that play a role in the pathogenic processes in ALS. By intervening on this, AMX0035 tries to reduce the loss of motor nerves and thus preserve more function. The available results from the phase 2 study show that a possible disease-retarding effect can be seen in participants. This slowing effect was measured with the ALSFRS-R, but was not apparent when measuring other outcomes such as muscle strength or lung function. In addition, the number of participants in the phase 2 study was still limited and the results from that study may also be due to chance. As a result, the data from the phase 2 remains controversial and the ongoing phase 3 study is necessary. The phase 3 Phoenix study examines whether the previously measured effects can really be attributed to the drug and determines the long-term safety of AMX0035.



While it seems to be unfair that patients in the US will most likely be able to have access to  Relyvrio, while those in Europe can only access the drug as part of a clinical trial, we from TRICALS believe that there is a very good scientific reason to complete the trial in Europe.  We do not know for definite that Relyvrio works, as the US study was limited in time and patient numbers. If all countries took the approach the FDA have taken, we would not be able to ever effectively establish if a treatment is really effective for people with MND.


We in TRICALS remains committed to providing the most effective therapies for all people suffering from this devastating disease as soon as possible. We will continue to conduct high quality studies that provide definitive results regarding benefits to people living with MND.


Notes to the editor:

TRICALS is the first international research initiative uniting patients, top researchers and ALS foundations to reach our one goal: find an effective treatment for ALS. For more see


Categories: Education and SupportNewsPress Releases